Target intelligence / Profile preview

Human papillomavirus type 11 L1 major capsid protein (HPV11 L1)

Target
HPV11 L1
Molecular classification
Viral protein, Capsid protein
01

Overview

The Human papillomavirus type 11 L1 major capsid protein is the primary structural component of the HPV11 viral capsid, which self-assembles into pentameric capsomeres and further into icosahedral virus-like particles (VLPs). HPV11 is a low-risk mucosal human papillomavirus responsible for approximately 90% of genital warts (condyloma acuminata) and recurrent respiratory papillomatosis. The L1 protein contains highly immunogenic, conformationally dependent epitopes located on its surface-exposed hypervariable loops. These conformational epitopes are the primary targets for neutralizing antibodies that block viral attachment to host cell heparan sulfate proteoglycans and subsequent internalization.

Prophylactic vaccines, such as the quadrivalent Gardasil and nonavalent Gardasil 9, utilize recombinant HPV11 L1 VLPs to elicit robust, type-specific neutralizing antibody responses that prevent initial infection. Because these vaccines are composed of empty capsids lacking viral DNA, they are non-infectious and non-oncogenic. Efficacy and immunogenicity are typically monitored by measuring serum anti-HPV11 L1 IgG and neutralizing antibody titers. While highly effective at preventing infection, these L1-targeted vaccines do not possess therapeutic efficacy against pre-existing HPV11 infections or lesions.

Other names
HPV11 L1 capsid protein conformational epitopesHuman papillomavirus type 11 L1 proteinHPV-11 L1 major capsid proteinHPV11 major capsid protein L1Human papillomavirus 11 L1 major capsid protein
02

Mechanism of action

Active immunization to induce type-specific neutralizing antibodies that block viral attachment and entry into host cells

03

Biological functions

Viral entryViral assemblyHost cell attachmentImmune response
04

Disease associations

InfectionGenital wartsLaryngeal papillomatosis
05

Safety considerations

Injection site reactionsFeverHeadacheFatigueSyncopeHypersensitivity reactions
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

Anti-HPV11 L1 IgG antibody titerHPV11 neutralizing antibody titerHPV11 DNA detection

Beyond the preview

Go deeper on Human papillomavirus type 11 L1 major capsid protein (HPV11 L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human papillomavirus type 11 L1 major capsid protein (HPV11 L1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call